Table 3.
Baseline characteristics of subjects randomized to simvastatin and placebo
| Placebo (n = 33) |
Simvastatin (n = 32) |
||
|---|---|---|---|
| Age,yrs | 51.0 ± 13.6 | 50.0 ± 14.3 | |
| Gender, Female | 30 (90.9) | 26 (81.2) | |
| Body mass index, kg/m2 | 27.8 ± 6.5 | 28.1 ± 7.7 | |
| Race/ethnicity | |||
| White (Non-Hispanic) | 20 (60.6) | 19 (59.4) | |
| Hispanic or Latino | 2 (6.1) | 7 (21.9) | |
| Black | 8 (24.2) | 5 (15.6) | |
| Asian | 3 (9.1) | 0 | |
| Other | 0 | 1 (3.1) | |
| PAH diagnosis | |||
| Idiopathic | 17 (53.1) | 16 (50) | |
| Heritable | 1 (3.1) | 2 (6.3) | |
| Congenital systemic-to-pulmonary shunt | 1 (3) | 5 (15.6) | |
| Systemic sclerosis | 7 (21.2) | 5 (15.6) | |
| Other connective tissue disease | 5 (15.2) | 4 (12.5) | |
| Drugs/toxins | 2 (6.3) | 0 | |
| Right ventricular systolic pressure by echocardiography, mm Hg |
(n=57) | 63.5 (50–81) | 82.0 (59–100) |
| Concomitant medications | |||
| Ambrisentan | 10 (30.3) | 8 (25.0) | |
| Bosentan | 9 (27.3) | 9 (28.1) | |
| Epoprostenol | 6 (18.9) | 9 (28.1) | |
| Iloprost (inhaled) | 5 (15.2) | 4 (12.5) | |
| Sildenafil | 21 (63.6) | 21 (65.6) | |
| Treprostinil (intravenous) | 3 (9.1) | 2 (6.3) | |
| Combination therapy | 22 (66.7) | 18 (56.3) | |
| Warfarin | 23 (69.7) | 28 (87.5) | |
| WHO functional classification | |||
| Class I | 5 (15.2) | 0 | |
| Class II | 18 (54.6) | 23 (71.9) | |
| Class III | 10 (30.3) | 9 (28.1) | |
| Six minute walk distance, m | 442.0 ± 128.8 | 422.9 ± 101.4 | |
| Post-test Borg Dyspnea Score | 3 (2–3) | 3 (2–3) | |
Data shown as mean ± standard deviation, median (interquartile range), or n (%).